[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Degeorges S, Mesnil A, Marion-Audibert AM, Bouafia-Sauvy F, Berger F, Bancel B, Barnoud R, Rode A, Péré-Vergé D, Souquet JC: [Ano-rectal symptoms, related to Epstein-Barr Virus-Associated Burkitt's lymphoma in an immunocompetent patient]. Gastroenterol Clin Biol; 2007 Apr;31(4):442-4
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ano-rectal symptoms, related to Epstein-Barr Virus-Associated Burkitt's lymphoma in an immunocompetent patient].
  • [Transliterated title] Manifestations anorectales, en rapport avec un lymphome de Burkitt associé au virus Epstein Barr, chez une malade immunocompétente.
  • Final diagnosis confirmed by biopsy performed during rectosigmoidoscopy was an Epstein-Barr Virus-Associated Burkitt's lymphoma.
  • Chemotherapy resulted in rapid regression of the tumoral mass.
  • [MeSH-major] Burkitt Lymphoma
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Female. Humans. Immunocompetence. Magnetic Resonance Imaging. Rectum / pathology. Sigmoidoscopy. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483786.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


2. Kast RE: Evidence that amphotericin B mediates reactivation of latent Epstein-Barr virus in Hodgkin's lymphoma allowing cytotoxicity by acyclovir. Yonsei Med J; 2006 Apr 30;47(2):287-90
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence that amphotericin B mediates reactivation of latent Epstein-Barr virus in Hodgkin's lymphoma allowing cytotoxicity by acyclovir.
  • This brief communication focuses on aspects of a recent case report (Yonsei Med J 2005;46:425-30) on a full and sustained remission of Hodgkin's lymphoma (HL) after a single day of chemotherapy.
  • A septic episode required stopping chemotherapy and starting amphotericin B and acyclovir.
  • A review of research supporting the notion that amphotericin B can reactivate latent Epstein-Barr virus and thus allow acyclovir to kill infected HL cells is given.
  • If successful, amphotericin B and acyclovir treatment could be extended to other EBV-driven cancers such as Burkitt's lymphoma, nasopharyngeal carcinoma and the occasional EBV-related epithelial cancer of the breast, colon, prostate, and others.
  • [MeSH-major] Acyclovir / therapeutic use. Amphotericin B / pharmacology. Drug Synergism. Herpesvirus 4, Human / metabolism. Hodgkin Disease / drug therapy. Hodgkin Disease / virology
  • [MeSH-minor] Anti-Bacterial Agents / pharmacology. Burkitt Lymphoma / virology. Ganciclovir / therapeutic use. Humans. Remission Induction. Tumor Necrosis Factor-alpha / metabolism. Virus Activation

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Yonsei Med J. 2005 Jun 30;46(3):425-30 [15988816.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):360-7 [11555713.001]
  • [Cites] Blut. 1990 Dec;61(6):346-9 [2291981.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5122-30 [12910249.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37561-8 [12860979.001]
  • [Cites] J Virol. 2004 Feb;78(4):1893-902 [14747554.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1755-62 [14604957.001]
  • [Cites] Antimicrob Agents Chemother. 1984 Jun;25(6):772-4 [6331301.001]
  • [Cites] J Virol. 2005 May;79(9):5875-9 [15827204.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Apr;49(4):1617-21 [15793154.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Mar;37(3):511-7 [15618006.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 17;96(22):1691-702 [15547182.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):384-8 [9458076.001]
  • [Cites] N Engl J Med. 1996 Sep 5;335(10):721-9 [8786764.001]
  • [Cites] Pharmacol Ther. 1994;64(3):529-64 [7724661.001]
  • (PMID = 16642564.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Tumor Necrosis Factor-alpha; 7XU7A7DROE / Amphotericin B; P9G3CKZ4P5 / Ganciclovir; X4HES1O11F / Acyclovir
  • [Other-IDs] NLM/ PMC2687644
  •  go-up   go-down


3. Hui KF, Chiang AK: Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. Int J Cancer; 2010 May 15;126(10):2479-89
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
  • In Epstein-Barr virus (EBV)-associated malignancies, the virus is harbored in every tumor cell and persists in tightly latent forms expressing a very limited number of viral latent proteins.
  • Induction of EBV lytic cycle leads to expression of a much larger number of viral proteins, which may serve as potential therapeutic targets.
  • We found that 4 histone deacetylase inhibitors, trichostatin A (TSA), sodium butyrate (SB), valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA), all significantly induced EBV lytic cycle in EBV-positive gastric carcinoma cells (AGS/BX1, latency II) but only weakly induced in Burkitt lymphoma cells (AK2003, latency I) and did not induce in lymphoblastoid cells (LCLs, latency III).
  • Interestingly, SAHA potently induced viral lytic cycle in AGS/BX1 cells at micromolar concentrations (evidenced by 8-fold increase in viral DNA replication, strong expression of viral lytic proteins and production of infectious virus particles) and mediated enhanced cell death of EBV-positive AGS/BX1 cells when compared with that of EBV-negative AGS cells, possibly related to cell cycle arrest at G2/M phase.
  • Furthermore, SAHA effected strong induction of EBV lytic cycle in nasopharyngeal carcinoma but not in NK lymphoma cells (both expressing EBV latency II pattern), indicating preferential viral lytic induction in epithelial rather than lymphoid malignancies.
  • In conclusion, SAHA is found to be a potent EBV lytic cycle inducing agent, which warrants further investigation into its potential application as a novel virus-targeted drug for treatment of EBV-associated epithelial malignancies.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Carcinoma / drug therapy. Carcinoma / virology. Herpesvirus 4, Human / drug effects. Histone Deacetylase Inhibitors / pharmacology. Hydroxamic Acids / pharmacology
  • [MeSH-minor] Blotting, Western. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / virology. Butyrates / pharmacology. Cell Cycle / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Fluorescent Antibody Technique. Humans. Leukemia / drug therapy. Leukemia / virology. Polymerase Chain Reaction. Stomach Neoplasms / drug therapy. Stomach Neoplasms / virology. Valproic Acid / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19816947.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Butyrates; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 3X2S926L3Z / trichostatin A; 58IFB293JI / vorinostat; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


Advertisement
4. Cordeiro A, Machado AI, Borges A, Alves MJ, Frade MJ: Burkitt's lymphoma related to Epstein-Barr virus infection during pregnancy. Arch Gynecol Obstet; 2009 Aug;280(2):297-300
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma related to Epstein-Barr virus infection during pregnancy.
  • SETTING: Burkitt's lymphoma is a rare form of cancer and is an extremely rare diagnosis during pregnancy.
  • This form of lymphoma is a very fast growing B cell neoplasm and chemotherapy is the treatment of choice for the disease in all its stages.
  • CASE REPORT: The authors describe the case of a Caucasian 40-year-old nulliparous woman, with previous known Epstein-Barr virus infection, that presents at 28 weeks gestation with supraclavicular adenopathy and multiple bilateral breast nodules, in which biopsy showed non-Hodgkin lymphoma, Burkitt's type.
  • DISCUSSION: There are few described cases of Burkitt's lymphoma during pregnancy and in general the outcomes have been poor.
  • This neoplasia is the most rapidly progressive human tumor, and any delay in initiating therapy can adversely affect patient's prognosis.
  • The authors discuss treatment options in pregnancy and its perinatal implications.
  • [MeSH-major] Burkitt Lymphoma / virology. Epstein-Barr Virus Infections / complications. Pregnancy Complications, Neoplastic / virology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Female. Humans. Pregnancy. Pregnancy Complications, Infectious

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107501.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Unholzer A, Starz H, Hirschsteiner O, Balda BR: [Gingival Burkitt lymphoma in a hepatitis C-positive renal transplant patient]. J Dtsch Dermatol Ges; 2005 Jan;3(1):46-51
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gingival Burkitt lymphoma in a hepatitis C-positive renal transplant patient].
  • [Transliterated title] Burkitt-Lymphom der Gingiva bei einem Hepatitis C-positiven nierentransplantierten Patienten.
  • Compared to the general population, the organ transplant patients have a 30-60 fold increased risk of developing non-Hodgkin's lymphoma.
  • A 55-year-old, hepatitis C-positive man developed an Epstein-Barr virus (EBV)- negative Burkitt lymphoma (BL) first appearing on the gingiva under immunosuppressive therapy nine years after allogenic renal transplantation.
  • In 70% of BL occurring after organ transplantation, genes or gene products related to EBV can be demonstrated within the tumor cells.
  • The EBV status of the tumor is of important prognostic significance: EBV-positive BL occurring in organ transplant patients usually responds well to reduction or cessation of immunosuppressive therapy; in some cases permanent complete remissions can be achieved even without chemotherapy.
  • In contrast, patients with EBV-negative BL have a very poor prognosis and hardly respond, even to aggressive chemotherapy protocols.
  • [MeSH-major] Burkitt Lymphoma / etiology. Gingival Neoplasms / etiology. Hepatitis C / complications. Immunocompromised Host. Kidney Transplantation
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Gingiva / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Time Factors. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353750.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


6. Navarro WH, Kaplan LD: AIDS-related lymphoproliferative disease. Blood; 2006 Jan 1;107(1):13-20
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphoproliferative disease.
  • Not long after the recognition of HIV as the causative agent of AIDS, it was evident that individuals infected with HIV developed lymphoma at a greater rate than the population at large.
  • Approximately two thirds of AIDS-related lymphoma (ARL) cases are categorized as diffuse large B-cell type, with Burkitt lymphomas comprising 25% and other histologies a much smaller proportion.
  • Recent clinical trials have demonstrated a better outcome with chemotherapy for ARL since the introduction of combination antiretroviral treatment, termed highly active antiretroviral therapy (HAART).
  • Coinfection with other viruses such as Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus have led to the genesis of previously rare or unrecognized lymphoma subtypes such as plasmablastic and primary effusion lymphomas.
  • The immunosuppressive impact of treatment for patients with ARL receiving chemotherapy with HAART appears transient and opportunistic infections have become less problematic than prior to HAART.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Hematopoietic Stem Cell Transplantation. Humans. Lymphoproliferative Disorders / therapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16099881.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 100
  •  go-up   go-down


7. Bibas M, Antinori A: EBV and HIV-Related Lymphoma. Mediterr J Hematol Infect Dis; 2009;1(2):e2009032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV and HIV-Related Lymphoma.
  • The overall prevalence of HIV-associated lymphoma is significantly higher compared to that of the general population and it continues to be relevant even after the wide availability of highly active antiretroviral therapy (HAART) (1).
  • Epstein-Barr virus (EBV), a γ-Herpesviruses, is involved in human lymphomagenesis, particularly in HIV immunocompromised patients.
  • It has been largely implicated in the development of B-cell lymphoproliferative disorders as Burkitt lymphoma (BL), Hodgkin disease (HD), systemic non Hodgkin lymphoma (NHL), primary central nervous system lymphoma (PCNSL), nasopharyngeal carcinoma (NC).
  • Virus-associated lymphomas are becoming of significant concern for the mortality of long-lived HIV immunocompromised patients, and therefore, research of advanced strategies for AIDS-related lymphomas is an important field in cancer chemotherapy.
  • Detailed understanding of the EBV lifecycle and related cancers at the molecular level is required for novel strategies of molecular-targeted cancer chemotherapy The linkage of HIV-related lymphoma with EBV infection of the tumor clone has several pathogenetic, prognostic and possibly therapeutic implications which are reviewed herein.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1999 Jun;26(3):346-56 [10375091.001]
  • [Cites] Blood. 2001 Jul 1;98(1):146-55 [11418474.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2339-44 [11588028.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1731-41 [11748275.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] Nat Med. 2002 Apr;8(4):319-23 [11927927.001]
  • [Cites] AIDS. 2002 May 24;16(8):1195-6 [12004285.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2321-7 [12406882.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15572-7 [12434018.001]
  • [Cites] Lancet. 2003 Jan 18;361(9353):217-23 [12547545.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2982-9 [12782607.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4166-78 [12907455.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):727-38 [15151213.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] J Pathol. 2008 Sep;216(1):83-92 [18566961.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):763-4 [18756546.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] J Exp Med. 1986 Dec 1;164(6):2049-60 [3491176.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1674-81 [8394878.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7635-9 [1652756.001]
  • [Cites] Lancet. 1991 Oct 19;338(8773):969-73 [1681341.001]
  • [Cites] J Exp Med. 1991 Jan 1;173(1):147-58 [1845872.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] Am J Hematol. 1989 Nov;32(3):200-4 [2816914.001]
  • [Cites] Cell. 1985 Dec;43(3 Pt 2):831-40 [3000618.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1758-67 [7541452.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1072-85 [8214003.001]
  • [Cites] J Virol. 1996 Feb;70(2):1143-53 [8551575.001]
  • [Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]
  • [Cites] Curr Opin Oncol. 1996 Sep;8(5):373-6 [9026061.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):16-23 [9892104.001]
  • [Cites] BMJ. 1999 Jul 3;319(7201):23-4 [10390454.001]
  • [Cites] Neurology. 2000 Feb 22;54(4):993-7 [10691003.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):282-5 [11175653.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Mar;18(3):563-72 [9090424.001]
  • [Cites] J Clin Invest. 1997 Apr 1;99(7):1525-33 [9119996.001]
  • [Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]
  • [Cites] J Clin Pathol. 1997 Nov;50(11):911-8 [9462239.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):623-30 [9502401.001]
  • [Cites] Haematologica. 1998 Jan;83(1):87-9 [9542326.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]
  • [Cites] AIDS. 2002 Oct 18;16(15):2001-11 [12370498.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]
  • [Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]
  • [Cites] Am J Hematol. 2003 Jul;73(3):143-8 [12827649.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):300-9 [12872349.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1768-74 [1373087.001]
  • [Cites] Am J Hematol. 2004 May;76(1):88-91 [15114607.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Neurology. 1997 Mar;48(3):687-94 [9065549.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Presse Med. 2004 Dec 4;33(21):1487-92 [15637794.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4339-44 [16076866.001]
  • [Cites] Clin Infect Dis. 2005 Oct 15;41(8):e76-9 [16163622.001]
  • [Cites] Hematol Oncol. 2005 Jun;23(2):61-7 [16216037.001]
  • [Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]
  • [Cites] J Gen Virol. 2006 May;87(Pt 5):1047-74 [16603506.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1233-6 [16938530.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2597-603 [17148591.001]
  • [Cites] Oncogene. 2007 Aug 2;26(35):5115-23 [17325665.001]
  • [Cites] Adv Anat Pathol. 2007 May;14(3):189-94 [17452815.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3715-21 [17682125.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3813-20 [18230756.001]
  • [Cites] Blood Rev. 2008 Sep;22(5):261-81 [18456377.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):195-204 [18502823.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1447-52 [9037073.001]
  • [Cites] AIDS. 1997 Oct;11(12):1522-3 [9342077.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 4;90(5):364-9 [9498486.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11963-8 [9751773.001]
  • [Cites] Immunity. 1998 Sep;9(3):405-11 [9768760.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1609-14 [9811353.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2119-27 [11684931.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Dermatology. 2004;208(3):287-90 [15118393.001]
  • [Cites] Clin Infect Dis. 2004 Jun 1;38(11):1629-32 [15156453.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2627-36 [15197806.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4227-8 [15483034.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • [Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Crit Rev Oncog. 1998;9(3-4):199-208 [10201628.001]
  • (PMID = 21416008.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033170
  •  go-up   go-down


8. Wade M, Allday MJ: Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins. Mol Cell Biol; 2000 Feb;20(4):1344-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins.
  • Several Epstein-Barr virus (EBV)-negative Burkitt lymphoma-derived cell lines (for example, BL41 and Ramos) are extremely sensitive to genotoxic drugs despite being functionally null for the tumor suppressor p53.
  • Surprisingly, latent infection of these genotoxin-sensitive cells with EBV protects them from both apoptosis and cell cycle arrest, allowing them to complete the division cycle.
  • However, a comparison with EBV-immortalized B-lymphoblastoid cell lines (which have functional p53) showed that EBV does not block apoptosis per se but rather abrogates the activation of, or signalling from, the checkpoint in G(2)/M.
  • Furthermore, analyses of BL41 and Ramos cells latently infected with P3HR1 mutant virus, which expresses only a subset of the latent viral genes, showed that LMP-1, the main antiapoptotic latent protein encoded by EBV, is not involved in the protection afforded here by viral infection.
  • Although steady-state levels of Bcl-2 and related proteins varied between BL41 lines and clones, they did not change significantly during apoptosis, nor was the level of any of these anti- or proapoptotic proteins predictive of the outcome of treatment.
  • We have demonstrated that a subset of EBV latent gene products can inactivate a cell cycle checkpoint for monitoring the fidelity and timing of cell division and therefore genomic integrity.
  • This is likely to be important in EBV-associated growth transformation of B cells and perhaps tumorigenesis.
  • Furthermore, this study suggests that EBV will be a unique tool for investigating the intimate relationship between cell cycle regulation and apoptosis.
  • [MeSH-major] G2 Phase / drug effects. Herpesvirus 4, Human / pathogenicity. Mitosis / drug effects. Mutagens / toxicity
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Apoptosis / physiology. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Burkitt Lymphoma / virology. Cisplatin / pharmacology. Drug Resistance / genetics. Gene Expression. Genes, Viral. Humans. Poly(ADP-ribose) Polymerases / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Cells, Cultured. Viral Matrix Proteins / physiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Oncogene. 1996 Nov 21;13(10):2243-54 [8950992.001]
  • [Cites] Biochim Biophys Acta. 1997 Oct 24;1333(2):F151-78 [9395285.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):940-6 [9500454.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1700-9 [9501091.001]
  • [Cites] Curr Opin Cell Biol. 1998 Apr;10(2):240-7 [9561848.001]
  • [Cites] Trends Microbiol. 1998 May;6(5):175-7; discussion 177-8 [9614338.001]
  • [Cites] J Virol. 1998 Oct;72(10):7900-8 [9733827.001]
  • [Cites] J Virol. 1996 Dec;70(12):8653-9 [8970991.001]
  • [Cites] Science. 1997 Jan 17;275(5298):343-9 [8994024.001]
  • [Cites] Genes Dev. 1998 Oct 1;12(19):2973-83 [9765199.001]
  • [Cites] Science. 1998 Nov 20;282(5393):1497-501 [9822382.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Mol Cell Biol. 1999 Feb;19(2):1438-49 [9891077.001]
  • [Cites] Curr Opin Cell Biol. 1998 Dec;10(6):749-58 [9914174.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1651-60 [10022853.001]
  • [Cites] J Biol Chem. 1992 Jun 25;267(18):12424-7 [1618749.001]
  • [Cites] J Biol Chem. 1992 Dec 5;267(34):24157-60 [1332946.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):847-9 [8479522.001]
  • [Cites] Cell. 1993 Sep 24;74(6):957-67 [8402885.001]
  • [Cites] Cell. 1994 Aug 26;78(4):539-42 [8069905.001]
  • [Cites] Cell. 1994 Oct 21;79(2):329-39 [7954799.001]
  • [Cites] Science. 1994 Nov 4;266(5186):807-10 [7973635.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] EMBO J. 1995 Apr 3;14(7):1382-91 [7729416.001]
  • [Cites] Cell. 1995 Jun 2;81(5):801-9 [7774019.001]
  • [Cites] Oncogene. 1995 Jun 15;10(12):2447-54 [7784096.001]
  • [Cites] Semin Cancer Biol. 1995 Apr;6(2):109-16 [7647307.001]
  • [Cites] Mol Cell Biol. 1995 Nov;15(11):5849-57 [7565737.001]
  • [Cites] Oncogene. 1995 Sep 21;11(6):1027-31 [7566960.001]
  • [Cites] EMBO J. 1995 Oct 16;14(20):4994-5005 [7588628.001]
  • [Cites] Nucleic Acids Res. 1996 Jan 1;24(1):141-6 [8594564.001]
  • [Cites] Genes Dev. 1996 May 1;10(9):1054-72 [8654922.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2555-61 [10072495.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1391-9 [10197600.001]
  • [Cites] Cell Death Differ. 1998 Aug;5(8):687-93 [10200524.001]
  • [Cites] J Gen Virol. 1999 Apr;80 ( Pt 4):987-95 [10211969.001]
  • [Cites] Nature. 1999 Jun 24;399(6738):806-9 [10391249.001]
  • [Cites] Nature. 1999 Jun 24;399(6738):809-13 [10391250.001]
  • [Cites] Nature. 1999 Jun 24;399(6738):814-7 [10391251.001]
  • [Cites] Oncogene. 2000 Feb 3;19(5):700-9 [10698515.001]
  • [Cites] J Virol. 1985 Sep;55(3):710-20 [2991591.001]
  • [Cites] J Virol. 1987 Dec;61(12):3870-8 [2824821.001]
  • [Cites] J Natl Cancer Inst. 1990 May 2;82(9):749-55 [1691303.001]
  • [Cites] J Virol. 1990 May;64(5):2309-18 [2157887.001]
  • [Cites] Nature. 1991 Feb 14;349(6310):612-4 [1705663.001]
  • [Cites] Cell. 1991 Jun 28;65(7):1107-15 [1648447.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3300-6 [1375849.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):1957-64 [8642305.001]
  • [Cites] J Virol. 1996 Jul;70(7):4849-53 [8676521.001]
  • [Cites] J Cell Biol. 1996 Aug;134(4):963-70 [8769420.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4610-3 [8840972.001]
  • [Cites] Nature. 1996 Nov 21;384(6606):213-4 [8918868.001]
  • [Cites] Nature. 1996 Nov 21;384(6606):273-6 [8918879.001]
  • [Cites] Mol Biol Cell. 1997 Jun;8(6):1013-23 [9201712.001]
  • (PMID = 10648620.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Mutagens; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Viral Matrix Proteins; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC85280
  •  go-up   go-down


9. Freudenberg S, Palma P, Grobholz R, Ngendahayo L, Post S: HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case. Dis Colon Rectum; 2005 Aug;48(8):1656-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case.
  • PURPOSE: This article describes and discusses primary Burkitt's lymphoma of the anus which is an extremely rare site of origin.
  • Histopathology and immunohistology provided evidence of an Epstein-Barr virus-associated Burkitt's lymphoma.
  • Chemotherapy in combination of virostatic therapy is the gold standard for treatment, but because of economic constraints surgical treatment was the only practicable intervention and an abdominoperineal resection of the anorectum was performed.
  • CONCLUSIONS: Because of the AIDS epidemic and the increase of anal malignant pathologies, anal Burkitt's lymphoma may appear more frequently.
  • Adequate treatment is available for only a small percentage of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034658.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Hishima T, Oyaizu N, Fujii T, Tachikawa N, Ajisawa A, Negishi M, Nakamura T, Iwamoto A, Hayashi Y, Matsubara D, Sasao Y, Kimura S, Kikuchi Y, Teruya K, Yasuoka A, Oka S, Saito K, Mori S, Funata N, Sata T, Katano H: Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy. Microbes Infect; 2006 Apr;8(5):1301-7
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy.
  • Recent introduction of highly active antiretroviral therapy (HAART) is reported to have reduced the incidence of lymphoma among HIV-infected individuals.
  • A clinicopathological study was performed on 86 AIDS-related lymphoma patients who were treated in Tokyo area from 1987 to 2005.
  • The incidence of lymphoma detected by autopsy was 27% (53 cases/198 autopsies).
  • Diffuse large B cell lymphoma was the most predominant histological subtype throughout the period (78%).
  • Burkitt's lymphoma (BL) increased from 2% in the pre-HAART era (before end-1997) to 13% in the HAART era, whereas incidence of BL did not vary between HAART users and non-users.
  • Epstein-Barr virus (EBV)-positive lymphoma decreased from 88% in the pre-HAART era to 58% in the HAART era, but did not differ significantly between HAART users (73%) and non-users (74%).
  • Nodal involvement of lymphoma increased from 14% in the pre-HAART era to 50% in the HAART era; however, central nervous system involvement decreased from 62 to 38%.
  • These data suggest that HAART might play a partial role in these changes, and the alteration in immunological backgrounds, such as EBV prevalence, is suggested as another leading cause of these changes in Japanese AIDS-related lymphoma.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16697236.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


11. Abdulkarim B, Sabri S, Zelenika D, Deutsch E, Frascogna V, Klijanienko J, Vainchenker W, Joab I, Bourhis J: Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. Oncogene; 2003 Apr 17;22(15):2260-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
  • The Epstein-Barr virus (EBV) is involved in the carcinogenesis of several human cancers such as nasopharyngeal carcinoma (NPC) and Burkitt lymphoma (BL).
  • Given the consistent role of EBV in transformation and maintenance of malignant phenotype, antiviral strategies provide an attractive approach to target EBV-expressing cells.
  • In that aim, we have tested the Cidofovir, which is an acyclic nucleoside phosphonate analog known to exert an antiproliferative activity in some human virus-related tumors.
  • Here, we show that Cidofovir induces a downregulation of the EBV oncoprotein LMP1 associated with a decrease of the antiapoptotic Bcl-2 and an increase of the proapoptotic Bax protein in Raji (BL) and C15 (NPC) cells.
  • Using BL cell line BL2 B95-8 (BL2 infected with the B95.8 strain of EBV), we addressed the relation between EBV genome expression and modulation of viral oncoproteins by Cidofovir and/or ionizing radiation (IR).
  • In addition, Cidofovir enhanced the radiation-induced apoptosis and the radiosensitivity through the proteolytic cleavage of death effectors caspase-9 and -3, which was specifically induced by combined treatment in EBV-positive cells compared to their negative counterparts.
  • Furthermore, the combined treatment in nude mice led to a complete tumor remission without increasing toxicity in two human EBV-related cancer xenografts (Raji and C15).
  • These results provide the basis for a novel anticancer strategy to enhance the therapeutic ratio of IR in EBV-related cancers.
  • [MeSH-major] Antiviral Agents / pharmacology. Burkitt Lymphoma / radiotherapy. Carcinoma / radiotherapy. Cytosine / analogs & derivatives. Cytosine / pharmacology. Epstein-Barr Virus Infections / radiotherapy. Gene Expression Regulation, Viral / drug effects. Herpesvirus 4, Human / drug effects. Nasopharyngeal Neoplasms / radiotherapy. Oncogene Proteins, Viral / biosynthesis. Organophosphonates. Organophosphorus Compounds / pharmacology. Proto-Oncogene Proteins / biosynthesis. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Radiation Tolerance / drug effects. Tumor Virus Infections / radiotherapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / radiation effects. Caspase 3. Caspase 9. Caspases / metabolism. Cell Division / drug effects. Combined Modality Therapy. Enzyme Activation / drug effects. Enzyme Activation / radiation effects. Female. Genes, bcl-2. Humans. Mice. Mice, Nude. Remission Induction. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism. Tumor Cells, Cultured / radiation effects. Tumor Cells, Cultured / transplantation. Tumor Cells, Cultured / virology. Tumor Stem Cell Assay. Viral Matrix Proteins / biosynthesis. Viral Matrix Proteins / genetics. Xenograft Model Antitumor Assays. bcl-2-Associated X Protein

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12700662.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / BAX protein, human; 0 / Bax protein, mouse; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Oncogene Proteins, Viral; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Viral Matrix Proteins; 0 / bcl-2-Associated X Protein; 8J337D1HZY / Cytosine; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Casp9 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9; EC 3.4.22.- / Caspases; JIL713Q00N / cidofovir
  •  go-up   go-down


12. Corapçioglu F, Olgun N, Sarialioglu F, Uysal KM, Oren H, Sercan O: MLL-AF4 gene rearrangement in a child with Epstein-Barr virus-related posttransplant B-cell lymphoma. J Pediatr Hematol Oncol; 2003 Sep;25(9):740-2
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MLL-AF4 gene rearrangement in a child with Epstein-Barr virus-related posttransplant B-cell lymphoma.
  • Recipients of solid organ allografts are known to be at increased risk of developing Epstein-Barr virus-related posttransplant lymphoproliferative diseases.
  • He was diagnosed with a Burkitt-like lymphoma based on bone marrow examination and the finding that the blastic cells in bone marrow were EBER-1 positive.
  • He was treated with a combined chemotherapy regimen.
  • [MeSH-major] Epstein-Barr Virus Infections. Immunosuppressive Agents / adverse effects. Liver Transplantation / adverse effects. Lymphoma, B-Cell / genetics. Oncogene Proteins, Fusion / genetics. Tumor Virus Infections

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12972812.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


13. Zhang YH, Duan YL, Yang J, Jin L, Zhou CJ, Gao ZF: [Clinical study of 40 children with Burkitt's and Burkitt-like lymphoma]. Zhonghua Er Ke Za Zhi; 2008 Mar;46(3):209-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of 40 children with Burkitt's and Burkitt-like lymphoma].
  • OBJECTIVE: To summarize the histological and clinical characteristics of 40 cases with Burkitt's and Burkitt-like lymphoma in children, to evaluate the effects of treatment with international regimen, and to explore the treatment-related complications and prognostic factors.
  • METHODS: Forty patients with Burkitt's and Burkitt-like lymphoma were registered in Beijing Children Hospital from Feb 2003 to Apr 2006.
  • Intensive, short-term chemotherapy witch was modified from LMB89 protocol was given to the patients.
  • RESULTS: Of the 40 patients, 30 were diagnosed as Burkitt's lymphoma (BL) and 10 as Burkitt-like lymphoma (BLL).
  • Antibody against Epstein-Barr virus (EBV-Ab) was positive in 19 cases at diagnosis, only 7 of the patients were positive for EBER.
  • The courses of treatment were approximately 2 - 8 months.
  • After chemotherapy, 35 patients (88.7%) were still alive during the one-year follow-up.
  • Of 5 patients who died, 2 died of infection, 2 died of lymphoma progression during chemotherapy, and 1 died of relapse.
  • CONCLUSION: Burkitt's and Burkitt-like lymphoma are the most common NHL in children with rapid clinical process.
  • Outcome was greatly improved by current intensive, short-term chemotherapy regimen, the 3-year EFS was 81.8% including the patients who were in advanced stage.
  • Childhood lymphoma with short clinical history, stage IV and residual disease after 3 months of therapy are associated with poor prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099711.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Chuang SS, Huang WT, Hsieh PP, Jung YC, Ye H, Du MQ, Lu CL, Cho CY, Hsiao SC, Hsu YH, Lin KJ: Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features. Histopathology; 2008 Mar;52(4):427-35
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features.
  • AIMS: To characterize the clinicopathological features of sporadic Burkitt lymphoma (BL).
  • METHODS AND RESULTS: A retrospective study of 17 paediatric and 14 adult BLs with history and histopathology review, immunohistochemistry, Epstein-Barr virus (EBV) in situ hybridization (EBER) and fluorescence in situ hybridization.
  • Twenty-eight patients received chemotherapy including 13/16 (81%) paediatric and 3/12 (25%) adult patients with appropriate regimens; 16 (57%) received CNS prophylaxis.
  • The poor outcome in adult patients might be related to incorrect diagnosis and inappropriate treatment.
  • [MeSH-major] Burkitt Lymphoma / pathology. Central Nervous System Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Child, Preschool. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / virology. Female. Genotype. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization, Fluorescence. Infant. Male. Middle Aged. Phenotype. RNA, Viral / analysis. RNA-Binding Proteins / analysis. Retrospective Studies. Ribosomal Proteins / analysis. Survival Rate. Taiwan / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315595.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Viral; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


15. López G, Marcilla F, Ramos C, Arazo P: [Association between meningeal Burkitt lymphoma and Epstein-Barr virus in an HIV-infected patient]. Enferm Infecc Microbiol Clin; 2007 Dec;25(10):658
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association between meningeal Burkitt lymphoma and Epstein-Barr virus in an HIV-infected patient].
  • [Transliterated title] Asociación de linfoma de Burkitt meníngeo y virus de Epstein-Barr en paciente infectada por el VIH.
  • [MeSH-major] Burkitt Lymphoma / virology. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology. Meningeal Neoplasms / virology. Spinal Cord Compression / etiology. Spinal Neoplasms / virology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Fatal Outcome. Female. HIV Infections / drug therapy. HIV Infections / virology. Humans. Lumbosacral Region. Middle Aged. Paraparesis / etiology. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053481.001).
  • [ISSN] 0213-005X
  • [Journal-full-title] Enfermedades infecciosas y microbiología clínica
  • [ISO-abbreviation] Enferm. Infecc. Microbiol. Clin.
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


16. Solassol J, Kreuzer KA, Lass U, Schmidt CA: Epstein-Barr virus DNA quantitation assessed by a real-time polymerase chain reaction in a case of Burkitt's lymphoma. Leuk Lymphoma; 2001 May;41(5-6):669-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus DNA quantitation assessed by a real-time polymerase chain reaction in a case of Burkitt's lymphoma.
  • A real-time PCR technique was used to quantify EBV DNA load in plasma, leukocytes, peritoneal cells, ascites and cerebrospinal fluid (CSF) at diagnosis and during the follow-up of a 21-year-old patient suffering from an abdominal form of EBV-associated Burkitt's lymphoma.
  • The EBV DNA load correlated well with the clinical and biological remission status of the patient after chemotherapy confirming that EBV DNA quantitation in plasma and leukocytes from peripheral blood can be considered as a marker of the tumor load and can be analyzed in parallel for monitoring of EBV-related malignancies.
  • [MeSH-major] Burkitt Lymphoma / virology. DNA, Viral / blood. Herpesvirus 4, Human / genetics

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11378585.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Viral
  •  go-up   go-down


17. Chen SW, Chang ST, Lu CL, Hwang WS, Tsao CJ, Huang WT, Chang KY, Chuang SS: Upper aerodigestive tract lymphoma in Taiwan. J Clin Pathol; 2010 Oct;63(10):888-93
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper aerodigestive tract lymphoma in Taiwan.
  • AIM: To better understand the spectrum of primary lymphomas in the upper aerodigestive tract, a common site of extranodal lymphoma.
  • MATERIALS AND METHODS: Lymphoma cases diagnosed at an institution in southern Taiwan from 1992 to 2007 were retrospectively studied with pathology and history review, immunohistochemistry, in situ hybridisation for Epstein-Barr virus (EBER-ISH), and statistical analysis.
  • Phenotypically, there were 45 (64%) B cell and 25 (36%) T cell or extranodal natural killer (NK)/T cell lymphoma (ENKL) including 42 (60%) diffuse large B cell lymphomas (DLBCLs), 22 (31%) ENKLs, three unspecified peripheral T cell lymphomas, two follicular lymphomas and one Burkitt lymphoma.
  • Most patients received chemotherapy with or without radiotherapy.
  • Univariate analysis revealed that sinonasal presentation, T or NK/T cell phenotype, raised lactate dehydrogenase (LDH) activity, and Ann Arbor stage III/IV diseases were associated with prognostically significant higher hazard ratio (HR) of lymphoma-related death.
  • CONCLUSIONS: Only a limited number of lymphoma entities occurred primarily in this anatomical region.
  • A relatively high incidence of EBV positivity was identified in DLBCLs in this anatomical region, and further studies are warranted to elucidate the clinicopathological significance of these tumours.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Child. Epidemiologic Methods. Epstein-Barr Virus Infections / complications. Female. Humans. L-Lactate Dehydrogenase / blood. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Lymphoma, B-Cell / virology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / therapy. Lymphoma, T-Cell / virology. Male. Middle Aged. Mouth Neoplasms / pathology. Mouth Neoplasms / therapy. Mouth Neoplasms / virology. Neoplasm Staging. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876320.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


18. Watts RG, Hilliard LM, Berkow RL: Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation. J Pediatr Hematol Oncol; 2002 Nov;24(8):622-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation.
  • Traditional chemotherapy results in tumor response, but toxicity and transplant rejection limit survival.
  • The authors treated seven patients with malignant lymphoma after organ transplant with chemotherapy tailored to individual patient response.
  • Chemotherapy consisted of vincristine, cyclophosphamide, and prednisone, with or without doxorubicin (Adriamycin; Pharmacia & Upjohn, Peapack, NJ, U.S.A.
  • Six of seven patients (86%) showed a complete response to treatment, with five of seven (71%) alive disease-free at 9 to 72 months (mean 38.2) after treatment.
  • The results show that chemotherapy tailored to individual patient response is a safe and effective therapy for malignant lymphoma arising in patients with posttransplant lymphoproliferative disorder.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoproliferative Disorders / etiology. Postoperative Complications / drug therapy
  • [MeSH-minor] Algorithms. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bleomycin / administration & dosage. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / etiology. Chemotherapy, Adjuvant. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Doxorubicin / administration & dosage. Epstein-Barr Virus Infections. Etoposide / administration & dosage. Fatal Outcome. Female. Heart Transplantation. Humans. Immunosuppression / adverse effects. Kidney Transplantation. Lung Neoplasms / drug therapy. Lung Neoplasms / etiology. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / etiology. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Remission Induction. Stomach Neoplasms / drug therapy. Stomach Neoplasms / etiology. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12439033.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; PROMACE-CytaBOM protocol
  •  go-up   go-down


19. Cheung TW: AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. "On the offensive--the Trojan Horse is being destroyed"--Part B: Malignant lymphoma. Cancer Invest; 2004;22(5):787-98
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. "On the offensive--the Trojan Horse is being destroyed"--Part B: Malignant lymphoma.
  • The impact of highly active antiretroviral therapy (HAART) on the incidence of non-Hodgkin's lymphoma was less obvious initially, although primary central nervous system lymphoma (PCNSL) has dropped precipitously since the introduction of HAART.
  • The pathogenesis of acquired immunodeficiency syndrome-related lymphoma is multifactorial.
  • Epstein-Barr virus plays a significant role in these diseases, especially Burkitt lymphoma and PCNSL.
  • Data regarding the effect of HAART on the natural history and treatment outcomes of these malignancies are emerging.
  • The possibility of direct and indirect roles of human immunodeficiency virus in the carcinogenesis suggests that antiretroviral therapy may be an important component of the treatment for these malignancies.
  • The simultaneous administration of HAART and chemotherapy does not appear to significantly alter the toxicity profile, although the information with respect to the interaction of HAART and chemotherapy is limited.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Lymphoma / immunology. Lymphoma / virology. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / virology


20. Kersten MJ, Van Oers RH: Management of AIDS-related non-Hodgkin's lymphomas. Drugs; 2001;61(9):1301-15
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of AIDS-related non-Hodgkin's lymphomas.
  • The incidence of non-Hodgkin's lymphoma in individuals infected with HIV is approximately 60- to 100-fold increased over the general population.
  • The majority of patients with AIDS-related lymphoma (ARL) present with stage III-IV disease and with B-symptoms.
  • Histologically, most tumours are either diffuse large cell lymphomas or Burkitt lymphomas.
  • Several factors, such as disrupted immune surveillance, Epstein-Barr virus infection, chronic antigenic stimulation, cytokine dysregulation and the acquisition of genetic lesions, are thought to contribute to the pathogenesis.
  • Results of treatment with polychemotherapy compare unfavourably to results in patients without HIV infection.
  • Since the advent of highly active antiretroviral therapy (HAART), there appears to be a decrease in the incidence of ARL.
  • In addition, the use of HAART in combination with chemotherapy and the use of new treatment modalities may improve the outcome of this disease.
  • [MeSH-major] Lymphoma, AIDS-Related / etiology. Lymphoma, AIDS-Related / therapy. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Hematopoietic Cell Growth Factors / therapeutic use. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Aug 1;78(3):517-26 [8697399.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1094-103 [9060550.001]
  • [Cites] Cancer. 1994 May 1;73(9):2400-7 [8168044.001]
  • [Cites] N Engl J Med. 1986 Apr 3;314(14):874-9 [3005862.001]
  • [Cites] Cancer. 1971 Jul;28(1):89-98 [4938894.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Blood. 1992 Jul 15;80(2):498-504 [1320956.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):269-76 [10563433.001]
  • [Cites] Cancer. 1991 Aug 15;68(4):842-52 [1855183.001]
  • [Cites] J Exp Med. 1992 Jul 1;176(1):169-76 [1377222.001]
  • [Cites] Nature. 1984 Nov 29-Dec 5;312(5993):449-50 [6095104.001]
  • [Cites] Int J Epidemiol. 1997 Apr;26(2):400-7 [9169177.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1099-107 [8099121.001]
  • [Cites] J Nucl Med. 1993 Apr;34(4):567-75 [8455072.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] J Acquir Immune Defic Syndr. 1993 Mar;6(3):265-71 [7680712.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1691-702 [8355036.001]
  • [Cites] Blood. 1991 Apr 1;77(7):1527-33 [1849034.001]
  • [Cites] Nat Med. 1997 Nov;3(11):1242-9 [9359699.001]
  • [Cites] Ann Hematol. 1994 Dec;69(6):281-90 [7993935.001]
  • [Cites] Eur J Cancer. 2000 Feb;36(3):363-7 [10708938.001]
  • [Cites] Ann Intern Med. 1990 Aug 15;113(4):276-82 [1973886.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1673-5 [3047875.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1758-67 [7541452.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6 [7966400.001]
  • [Cites] Blood. 1991 Mar 1;77(5):1092-5 [1847310.001]
  • [Cites] Leuk Lymphoma. 1992 Oct;8(3):213-20 [1283356.001]
  • [Cites] J Clin Oncol. 1999 Feb;17 (2):554-60 [10080599.001]
  • [Cites] Leuk Lymphoma. 1994 Jul;14(3-4):263-71 [7950915.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):3026-35 [8918501.001]
  • [Cites] AIDS. 1996 Jan;10(1):61-7 [8924253.001]
  • [Cites] Eur J Cancer. 1991;27(11):1416-23 [1660293.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1840-7 [10547559.001]
  • [Cites] Lancet. 1991 Oct 19;338(8773):969-73 [1681341.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Blood. 1993 Jul 15;82(2):619-24 [8392401.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1838-42 [10068655.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Science. 1986 Sep 5;233(4768):1084-6 [3016902.001]
  • [Cites] Blood. 1994 May 15;83(10):2952-61 [8180391.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] J Infect Dis. 1994 Jul;170(1):198-202 [8014498.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1289-98 [1325212.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3601-6 [9817281.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2391-7 [10590382.001]
  • [Cites] J Clin Oncol. 1987 Sep;5(9):1322-8 [2442321.001]
  • [Cites] J Natl Cancer Inst. 1997 Feb 19;89(4):301-7 [9048834.001]
  • [Cites] Am J Epidemiol. 1993 Jan 1;137(1):19-30 [8434570.001]
  • [Cites] Mol Cell Biol. 1986 Nov;6(11):3838-46 [3025615.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1982 Jun 4;31(21):277-9 [6808345.001]
  • [Cites] Med Oncol. 1998 Apr;15(1):50-7 [9643531.001]
  • [Cites] Blood. 1998 Feb 1;91(3):747-55 [9446632.001]
  • [Cites] Blood. 1990 Dec 1;76(11):2303-10 [2257304.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1135-8 [9834829.001]
  • [Cites] Ann Oncol. 1992 Dec;3(10):843-7 [1286047.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3423-30 [7780129.001]
  • [Cites] Br J Haematol. 1995 Aug;90(4):844-9 [7669663.001]
  • [Cites] JAMA. 1989 Feb 3;261(5):719-24 [2536124.001]
  • [Cites] J Clin Invest. 1997 Apr 1;99(7):1525-33 [9119996.001]
  • [Cites] Am J Med. 1993 Aug;95(2):188-96 [7689296.001]
  • [Cites] Ann Hematol. 1999 Jan;78(1):9-12 [10037262.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4612-6 [8541552.001]
  • [Cites] Ann Intern Med. 1996 Apr 1;124(7):654-63 [8607594.001]
  • [Cites] Ann Intern Med. 1988 May;108(5):744-53 [3358573.001]
  • [Cites] JAMA. 1991 Jul 3;266(1):84-8 [1710673.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9809-14 [10449776.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] J Exp Med. 1986 Dec 1;164(6):2049-60 [3491176.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1071-2 [10744095.001]
  • [Cites] Haematologica. 1998 Jun;83(6):508-13 [9676023.001]
  • [Cites] Ann Neurol. 1988;23 Suppl:S13-6 [2894803.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1978-84 [7692000.001]
  • [Cites] Leukemia. 1993 Oct;7(10):1621-9 [8412324.001]
  • [Cites] J Clin Oncol. 1991 Jun;9(6):929-40 [2033429.001]
  • [Cites] Blood. 1993 Apr 1;81(7):1889-97 [8461474.001]
  • [Cites] J Exp Med. 1994 Dec 1;180(6):2371-6 [7964510.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):328-32 [8625110.001]
  • [Cites] Ann Oncol. 1990;1(3):203-11 [2261366.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S31-3 [10430216.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1781-7 [1356511.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S11-7 [10430212.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):795-8 [10354149.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1674-81 [8394878.001]
  • [Cites] Blood. 1997 May 15;89(10):3755-62 [9160681.001]
  • (PMID = 11511024.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Hematopoietic Cell Growth Factors
  • [Number-of-references] 96
  •  go-up   go-down


21. Au WY, Ma ES, Choy C, Chung LP, Fung TK, Liang R, Kwong YL: Therapy-related lymphomas in patients with autoimmune diseases after treatment with disease-modifying anti-rheumatic drugs. Am J Hematol; 2006 Jan;81(1):5-11
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related lymphomas in patients with autoimmune diseases after treatment with disease-modifying anti-rheumatic drugs.
  • Ten patients developing lymphomas after disease modifying anti-rheumatic drugs (DMARD) (methotrexate, n = 3, mean cumulative dose = 3.4 g; cyclophosphamide, n = 2, mean dose = 70 g; azathioprine, n = 6, mean dose = 243 g) were investigated.
  • Methotrexate-related lymphomas were Epstein-Barr virus (EBV)-positive, had infrequent aberrant methylation of p15 and p16, and responded well to methotrexate withdrawal or anti-CD20 antibody (rituximab) alone without concomitant chemotherapy, implying that defective immunosurveillance was important in lymphomagenesis.
  • However, 75% of cyclophosphamide/azathioprine-related lymphomas were EBV-negative, had frequent p15 and p16 methylation, and responded poorly to drug withdrawal and chemotherapy, implying that direct drug-induced mutagenesis might be involved in lymphomagenesis.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Antirheumatic Agents / administration & dosage. Autoimmune Diseases / drug therapy. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cell Transformation, Viral / drug effects. Cyclin-Dependent Kinase Inhibitor p15 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. DNA Methylation / drug effects. Female. Herpesvirus 4, Human / metabolism. Humans. Male. Middle Aged. Mutagenesis / drug effects. Retrospective Studies. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16369970.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


22. Hachem RR, Chakinala MM, Yusen RD, Lynch JP, Aloush AA, Patterson GA, Trulock EP: Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome. Transplantation; 2004 Feb 15;77(3):431-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median time from transplantation to the onset of LPD was 5.8 years.
  • The time to diagnosis of LPD was significantly shorter for Epstein-Barr virus (EBV)-seronegative than for EBV-seropositive recipients (median, 175 vs. 2255 days; log-rank, P<0.001).
  • Seventeen cases were non-Hodgkin's lymphomas, one was a Burkitt's lymphoma, and one was an atypical lymphoid proliferation.
  • Immunosuppressive therapy was decreased in all patients.
  • Eleven underwent surgical resection, and nine received chemotherapy.
  • The median time from the diagnosis of LPD to death was 68 days.
  • CONCLUSIONS: Abdominal-pelvic LPD is typically a late complication after lung transplantation; however, when it occurs early, it may be related to a primary EBV infection.
  • This form of LPD is most frequently a non-Hodgkin's lymphoma, and despite aggressive therapy, the prognosis is poor.
  • [MeSH-minor] Burkitt Lymphoma / etiology. Dose-Response Relationship, Drug. Epstein-Barr Virus Infections / complications. Female. Gastrointestinal Diseases / etiology. Humans. Immunosuppressive Agents / administration & dosage. Lymphoma, Non-Hodgkin / etiology. Male. Middle Aged. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14966421.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


23. Kataoka K, Seo S, Sugawara Y, Ota S, Imai Y, Takahashi T, Fukayama M, Kokudo N, Kurokawa M: Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. Leuk Lymphoma; 2010 Aug;51(8):1494-501
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated 323 consecutive patients undergoing adult-to-adult LDLT and identified three patients who developed biopsy-proven PTLD.
  • All of them were seropositive for Epstein-Barr virus (EBV) and had hepatitis C virus-related cirrhosis at transplant.
  • All three patients developed late-onset and monomorphic PTLD, including one diffuse large B-cell lymphoma and two Burkitt lymphomas with c-myc rearrangement.
  • Two of them were EBV negative.
  • The initial therapy included chemotherapy, rituximab, and immunosuppression withdrawal.
  • One patient died of sepsis during treatment and two patients achieved complete responses.
  • [MeSH-minor] Adolescent. Adult. Aged. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / virology. Female. Herpesvirus 4, Human / isolation & purification. Humans. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Review Literature as Topic. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Aug;51(8):1393-4 [20497000.001]
  • (PMID = 20578817.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Li N, Thompson S, Schultz DC, Zhu W, Jiang H, Luo C, Lieberman PM: Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One; 2010 Apr 12;5(4):e10126
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Epstein-Barr Virus (EBV) latent infection is associated with several human malignancies and is a causal agent of lymphoproliferative diseases during immunosuppression.
  • While inhibitors of herpesvirus DNA polymerases, like gancyclovir, reduce EBV lytic cycle infection, these treatments have limited efficacy for treating latent infection.
  • EBNA1 is an EBV-encoded DNA-binding protein required for viral genome maintenance during latent infection.
  • Four structurally related compounds were found to inhibit EBNA1-DNA binding in biochemical assays with purified EBNA1 protein.
  • Three of these compounds inhibited EBNA1 transcription activation function in cell-based assays and reduced EBV genome copy number when incubated with a Burkitt lymphoma cell line.
  • CONCLUSIONS: These experiments provide a proof-of-principle that virtual screening can be used to identify specific inhibitors of EBNA1 that may have potential for treatment of EBV latent infection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Med Virol. 2000 Mar-Apr;10(2):83-100 [10713596.001]
  • [Cites] J Biol Chem. 2008 May 9;283(19):12819-30 [18337247.001]
  • [Cites] J Med Chem. 2003 Jun 5;46(12):2287-303 [12773034.001]
  • [Cites] J Med Chem. 2003 Jun 19;46(13):2656-62 [12801229.001]
  • [Cites] J Comput Aided Mol Des. 2002 Dec;16(12):883-902 [12825621.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10989-94 [12947043.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14269-74 [14603034.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Nature. 1985 Feb 28-Mar 6;313(6005):812-5 [2983224.001]
  • [Cites] Cell. 1985 Oct;42(3):859-68 [2996781.001]
  • [Cites] J Virol. 1990 May;64(5):2369-79 [2157891.001]
  • [Cites] Cell. 1995 Oct 6;83(1):39-46 [7553871.001]
  • [Cites] Cell. 1996 Mar 8;84(5):791-800 [8625416.001]
  • [Cites] Proteins. 1998 Oct 1;33(1):74-87 [9741846.001]
  • [Cites] J Mol Biol. 1998 Dec 18;284(5):1273-8 [9878348.001]
  • [Cites] J Chem Inf Model. 2005 Jan-Feb;45(1):177-82 [15667143.001]
  • [Cites] Anal Biochem. 2005 May 15;340(2):259-71 [15840499.001]
  • [Cites] EMBO J. 2005 Apr 6;24(7):1406-17 [15775975.001]
  • [Cites] Mol Cell Biol. 2006 Feb;26(3):1124-34 [16428463.001]
  • [Cites] Virology. 2006 Mar 15;346(2):385-93 [16343579.001]
  • [Cites] Chem Biol. 2006 Jul;13(7):745-51 [16873022.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14188-93 [16966603.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7391-6 [17463090.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Oct 15;17(20):5652-5 [17766109.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27401-11 [12015325.001]
  • (PMID = 20405039.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093606; United States / NINDS NIH HHS / NS / R21 NS063906; United States / NCI NIH HHS / CA / R01CA093606; United States / NINDS NIH HHS / NS / R21NS063906
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Viral Proteins; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2853575
  •  go-up   go-down


25. Corti M, Villafañe Fioti MF, Lewi D, Schtirbu R, Narbaitz M, de Dios Soler M: [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients]. Acta Gastroenterol Latinoam; 2006 Dec;36(4):190-6
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Non-Hodgkin's lymphoma (NHL) is the second most common neoplasm among patients with AIDS.
  • All patients were staged by computed tomography scanning and bone marrow examination, in addition to the endoscopic evaluation.
  • RESULTS: All patients were males; 4 were heterosexual, 2 homosexual, and 1 were a hemophilic and an intravenous drug abuser.
  • The median age was 42 years and the median CD4 T cell count was 87 cells/uL at the time of the diagnosis of neoplasm.
  • No patient was receiving highly active antiretroviral therapy (HAART) at lymphoma diagnosis.
  • The global incidence of AIDS-associated lymphomas (central nervous system lymphomas, non-Hodgkin lymphomas and Hodgkin lymphoma) during the time of study was 2,9% (54 cases); 17 patients (32%) had diagnosis of systemic NHL; 10 (58,8%) of them were extranodal at the onset of clinical symptoms and 8 (80%) involvement the digestive tract and anexal glands (parotid gland, cavum, esophagus, stomach, duodenum, the right colon in 2 patients and the liver), as primary NHL of high grade and "B" phenotype.
  • All patients presented "B" symptoms at the time of diagnosis.
  • Primary duodenal lymphoma was the only Burkitt lymphoma of this serie and we detected the Epstein-Barr virus genome in the biopsy smears of this tumor and in the hepatic lymphoma.
  • Four patients were treated with systemic chemotherapy with granulocitic growth factor support plus highly active antiretroviral therapy (HAART); 2 of them (cavum and one of the colon) had a prolonged survival with immune reconstitution during 5 and 6 years, respectively, after the diagnosis.
  • The median survival of the patients, which received HAART plus chemotherapy, was 33 months.
  • Early diagnosis followed by chemotherapy plus HAART are necessary to improve the prognosis and the survival of these patients.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225446.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


26. Mwanda WO, Whalen C, Remick SC: Burkitt's lymphoma and emerging therapeutic strategies for EBV and AIDS-associated lymphoproliferative diseases in East Africa. East Afr Med J; 2005 Sep;82(9 Suppl):S133-4
MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma and emerging therapeutic strategies for EBV and AIDS-associated lymphoproliferative diseases in East Africa.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Burkitt Lymphoma / drug therapy. Epstein-Barr Virus Infections / drug therapy. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / drug therapy. Lymphoproliferative Disorders / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619688.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Grant] United States / PHS HHS / / A136219; United States / FIC NIH HHS / TW / TW00011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Kenya
  •  go-up   go-down






Advertisement